X
Healthcare Jun 20, 2022 09:44 AM (GMT+8) · EqualOcean
On June 17, Baiyang pharmaceutical and Shanghai Yizhong jointly held the Zisheng listing meeting of "opening a new era of paclitaxel · highly effective targeted chemotherapy". Professor wuyilong of Guangdong Provincial People's Hospital, Professor hanbaohui of Shanghai Chest Hospital, Professor shimeiqi of Jiangsu cancer hospital and other well-known experts shared the outstanding clinical effects of Zisheng in targeted chemotherapy. Paclitaxel micelle Zisheng ® It was approved on October 26, 2021. In February this year, Shanghai Yizhong cooperated with Baiyang pharmaceutical, a third-party commercialization platform. Zisheng's commercialization process has attracted the attention of the industry. The two sides hope to further promote the rapid entry of local innovative pharmaceutical achievements into the clinical scene through this listing meeting, so as to provide better treatment options for doctors and patients.

This text is a result of machine translation.